Trial · NCT07445295
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence and severity of adverse events | Run-in period.From the enrollment until 28 days after the last dose | Defined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAEV5.0) |
| Primary | OS | Randomized controlled period. From the first dose to death or end of study, an average of 2 year | Overall survival |
| Secondary | ORR | Run-in period and Randomized controlled period. From the first dose to disease progression or end of study, an average of 2 year | Objective Response Rate |
| Secondary | DoR | Run-in period and Randomized controlled period. From the first dose to disease progression or end of study, an average of 2 year | Duration of Response |
| Secondary | DCR | Run-in period and Randomized controlled period. From the first dose to disease progression or end of study, an average of 2 year | Disease control rate |
| Secondary | PFS | Run-in period and Randomized controlled period. From the first dose to disease progression or end of study, an average of 2 year | Progression free survival |
| Secondary | OS | Run-in period. From the first dose to death or end of study, an average of 2 year | Overall survival |
| Secondary | TTR | Randomized controlled period. From the first dose to disease progression or end of study, an average of 2 year | Time to Response |
| Secondary | Incidence and severity of adverse events | Randomized controlled period. From the enrollment until 28 days after the last dose | Defined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAEV5.0) |
| Secondary | QoL | Randomized controlled period. From the first dose to disease progression or end of study, an average of 2year | Quality of Life assessed by EORTC Quality of Life Questionnaire-Pancreatic Cancer Module 26 (EORTC QLQ-PAN26). The scale consists of 26 items, covering 14 dimensions including pain, indigestion, and satisfaction with healthcare, with scores ranging from 0 to 100. For symptom dimensions, higher scores indicate more severe symptoms; for functional/psychological dimensions, higher scores reflect better functioning or greater satisfaction. |
| Secondary | Time to maximum concentration (Tmax) | Run-in period and Randomized controlled period. From the first dose to end of chiauranib treatment, an average of 2year | PK Profile |
| Secondary | Maximum plasma concentration (Cmax) | Run-in period and Randomized controlled period. From the first dose to end of chiauranib treatment, an average of 2year | PK Profile |
| Secondary | Area under the plasma concentration-time curve (AUC) | Run-in period and Randomized controlled period. From the first dose to end of chiauranib treatment, an average of 2year | PK Profile |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07445295/registered